logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Effector Therapeutics, Inc.

USPTO Granted Patents = 22

% Expired Patents = 13.6



Trademarks = 2

Forward Citations = 75

Loading Chart...
Loading Chart...

31 inventors (with patents filed for the assignee):

goldMedal Justin T Ernst (15 out of 22 patents)

silverMedal Paul A Sprengeler (15 out of 16 patents)

bronzeMedal Siegfried Heinz Reich (14 out of 50 patents)

4.  Alan X Xiang (10 out of 19 patents)

5.  Stephen Evan Webber (8 out of 54 patents)

6.  Samuel Sperry (5 out of 5 patents)

7.  Chinh Viet Tran (5 out of 35 patents)

8.  Christian Nilewski (4 out of 5 patents)

9.  Theo Michels (4 out of 5 patents)

10.  Garrick Kenneth Packard (4 out of 21 patents)

11.  Kevin R Webster (4 out of 4 patents)

12.  Peggy A Thompson (3 out of 4 patents)

13.  Mike Shaghafi (2 out of 2 patents)

14.  Bennett C Borer (2 out of 14 patents)

15.  Jo Ann Z Wilson (2 out of 2 patents)


22 patents:

1. 12655161 - Solid forms of an eIF4E inhibitor (2026-06-16),
2. 11952375 - Crystalline forms of Mnk inhibitors (2024-04-09),
3. 11878015 - Piperidine-substituted Mnk inhibitors and methods related thereto (2024-01-23),
4. 11576933 - Compositions and methods for an improved antitumor immune response (2023-02-14),
5. 11564947 - Methods and compositions for cellular immunotherapy (2023-01-31),
6. 11440917 - EIF4A-inhibiting compounds and methods related thereto (2022-09-13),
7. 11286268 - EIF4E-inhibiting compounds and methods (2022-03-29),
8. 11130757 - Crystalline forms of MNK inhibitors (2021-09-28),
9. 11083727 - Piperidine-substituted Mnk inhibitors and methods related thereto (2021-08-10),
10. 11014926 - Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2 (2021-05-25),
11. 10793551 - Benzimidazole-indole inhibitors of Mnk1 and Mnk2 (2020-10-06),
12. 10780119 - Methods and compositions for cellular immunotherapy (2020-09-22),
13. 10702526 - Inhibitors of immune checkpoint modulators and related methods (2020-07-07),
14. 10577378 - EIF4A-inhibiting compounds and methods related thereto (2020-03-03),
15. 10576098 - Compositions and methods for treating fibrotic disease (2020-03-03),
Company Overview
Effector Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for cancer and other serious diseases. The company specializes in the discovery and advancement of small molecule drugs that target specific pathways involved in disease progression. With a commitment to precision medicine, Effector aims to improve patient outcomes through its proprietary technology platforms, which enable the identification of novel therapeutic candidates tailored to individual patient needs.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Effector Therapeutics, Inc. USPTO Patent Assignee Logo
22 Patents

#274 in San Diego, CA

#3,590 in California

#15,051 in US

#28,807 in the World

San Diego, CA (US)
San Diego, CA, United States of America

Effector Therapeutics, Inc.

Forward Citations = 75

31 inventors:

goldMedal Justin T Ernst (15 out of 22 patents)

silverMedal Paul A Sprengeler (15 out of 16 patents)

bronzeMedal Siegfried Heinz Reich (14 out of 50 patents)

4.  Alan X Xiang (10 out of 19 patents)

5.  Stephen Evan Webber (8 out of 54 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Effector Therapeutics, Inc.. Retrieved from https://idiyas.com/company/effector-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…